Tranexamic Acid After Pathological Fracture Treated With Modular Arthroplasty: Retrospective Observational Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 110
- 试验地点
- 1
- 主要终点
- Number of participants who require a blood transfusion.
研究概览
简要总结
This study assesses the safety and efficacy of TXA for patients treated for pathological femur fractures using modular prosthetics.
详细描述
Tranexamic acid is an efficacious medication for curtailing blood loss, haemoglobin drop, and the requirement for transfusions. Additionally, it is a secure medication, even when administered to oncology patients receiving reduction haemarthroplasty for pathological femoral fractures.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patological fracture
- •Arthroplasty using a modular prosthesis.
排除标准
- •threatened fracture
- •intraoperative blood transfusion
- •fracture fixation
研究组 & 干预措施
TXA
Tranexamic acid was administered to the participants at a dose of 1.0 g during the induction of anaesthesia and immediately after the operation.
干预措施: Tranexamic acid injection (Drug)
结局指标
主要结局
Number of participants who require a blood transfusion.
时间窗: During Hospitalization (up to day 10)
Need of blood transfusion
次要结局
- Estimeted blood lost after surgery.(During Hospitalization (up to day 3))
- Number of participants with embolic complication.(During Hospitalization (up to day 10))
研究者
Piotr Biega
Principal Investigator, Rzeszow University of Technology - Assistant Professor
Podkarpackie Oncological Center